Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lunchbox: Cisplatin/RT vs Sandwich Therapy in Endometrial Cancer
NCT02501954Phase 3Completed
- Sponsor
- Women's Cancer Care Associates
- Start
- Mar 2015
- Primary completion
- Nov 2023
- Modality
- Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of Cisplatin micelle injection (HA132) in endometrial cancer (EC) (2 arms), sponsored by Women's Cancer Care Associates. Primary endpoint: Recurrence-Free Survival at 8 years. Started Mar 2015; status: completed.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT02501954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02501954.